Ensysce Biosciences Insiders
ENSCWDelisted Stock | USD 0.01 0.0008 8.16% |
Ensysce Biosciences employs about 6 people. The company is managed by 6 executives with a total tenure of roughly 14 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Recap of Ensysce Biosciences' management performance can provide insight into the venture performance.
Geoff Birkett Insider Chief Officer |
MSE MBA Insider Chief Officer |
Ensysce |
Ensysce Biosciences Management Team Effectiveness
Ensysce Biosciences' management efficiency ratios could be used to measure how well Ensysce Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Ensysce Biosciences Workforce Comparison
Ensysce Biosciences is one of the top stocks in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 621. Ensysce Biosciences maintains roughly 6.0 in number of employees contributing less than 1% to stocks in Biotechnology industry.
Ensysce Biosciences Notable Stakeholders
An Ensysce Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Ensysce Biosciences often face trade-offs trying to please all of them. Ensysce Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Ensysce Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Geoff Birkett | Chief Officer | Profile | |
MSE MBA | Chief Officer | Profile | |
Lynn Kirkpatrick | CEO Director | Profile | |
Jeffrey Millard | Chief Officer | Profile | |
William Schmidt | Chief Officer | Profile | |
David Humphrey | Chief Officer | Profile |
About Ensysce Biosciences Management Performance
The success or failure of an entity such as Ensysce Biosciences often depends on how effective the management is. Ensysce Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Ensysce management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Ensysce management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. Its products treat severe pain and assist in preventing deaths caused by opioid abuse. Ensysce Biosciences operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Please note, the imprecision that can be found in Ensysce Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Ensysce Biosciences. Check Ensysce Biosciences' Beneish M Score to see the likelihood of Ensysce Biosciences' management manipulating its earnings.
Ensysce Biosciences Workforce Analysis
Traditionally, organizations such as Ensysce Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Ensysce Biosciences within its industry.Ensysce Biosciences Manpower Efficiency
Return on Ensysce Biosciences Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 4.9M | |
Net Loss Per Executive | 4.9M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Ensysce Pink Sheet
If you are still planning to invest in Ensysce Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ensysce Biosciences' history and understand the potential risks before investing.
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |